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Abstract
Background: The investigation of rare familial forms of kidney cancer has provided important insights into the biology of
sporadic renal cell carcinoma (RCC). In particular, the identification of the von Hippel Lindau (VHL) familial cancer syndrome
gene (VHL) provided the basis for the discovery that VHL is somatically inactivated in most sporadic clear cell RCC. Many
cases of familial RCC do not have mutations in known RCC susceptibility genes and there is evidence that genetic modifiers
may influence the risk of RCC in VHL disease patients. Hence we hypothesised that low-penetrance functional genetic
variants in pathways related to the VHL protein (pVHL) function might (a) modify the phenotypic expression of VHL disease
and/or (b) predispose to sporadic RCC.
Methodology/Principal Findings: We tested this hypothesis for functional polymorphisms in CDH1 (rs16260), IGFBP3
(rs2854744), MMP1 (rs1799750), MMP3 (rs679620), STK15 (rs2273535) and VEGF (rs1570360). We observed that variants of
MMP1 and MMP3 were significant modifiers of RCC risk (and risks of retinal angioma and cerebellar haemangioblastoma) in
VHL disease patients. In addition, higher frequencies of the MMP1 rs1799750 2G allele (p=0.017, OR 1.49, 95%CI 1.06–2.08)
and the MMP1/MMP3 rs1799750/rs679620 2G/G haplotype (OR 1.45, 95%CI 1.01–2.10) were detected in sporadic RCC
patients than in controls (n=295).
Conclusions/Significance: These findings (a) represent the first example of genetic modifiers of RCC risk in VHL disease, (b)
replicate a previous report of an association between MMP1/MMP3 variants and sporadic RCC and (c) further implicate
MMP1/MMP3-related pathways in the pathogenesis of familial and sporadic RCC.
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Introduction
Familial renal cell carcinoma (RCC) accounts for 2–3% of all
patients with RCC, but the investigation of rare familial forms
of kidney cancer has provided important insights into the
pathogenesis of non-familial RCC. Thus germline mutations in
the von Hippel-Lindau (VHL) disease tumour suppressor gene
(VHL) are the most common cause of familial renal cell
carcinoma and somatic inactivation of VHL occurs in most
sporadic clear cell RCC [1–4]. Hence the VHL tumour
suppressor gene product (pVHL) has a key ‘‘gatekeeper’’ role
in the pathogenesis of RCC [5]. Inherited mutations in a variety
of other genes including MET, FLCN, FH and SDHB may also
be associated with inherited RCC [6–7]. However, many cases
of familial RCC do not have a mutation in known RCC
susceptibility genes [8–9]. Furthermore, genetic modifier effects
may influence the risk of RCC in VHL disease [10–11]. These
observations suggest that unknown genetic factors contribute to
the development of RCC. A variety of approaches have been
employed in order to identify novel genetic causes of RCC
including the mapping and characterisation of RCC-associated
constitutional translocations (see 12 and references within) and
genetic association studies [13-15]. We hypothesised that
functional genetic variants in pathways related to pVHL
function might modify the phenotypic expression of VHL
disease and/or predispose to sporadic RCC. We tested this
hypothesis for polymorphisms in CDH1, IGFBP3, MMP1,
MMP3, STK15 and VEGF. Polymorphic variants in CDH1
(rs16260 at c.-160), IGFBP3 (rs2854744 at c.-202), MMP1
(rs1799750 at c.-1607) and VEGF (rs1570360 at c.-1154) had
previously been reported to alter promoter function [16-19]. In
addition, missense substitutions in STK15 and MMP3 (rs2273535
(p.Phe31Ile) and rs679620 (p.K45E) respectively) were also
analysed.
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6037Methods
Patient Groups
219 patients and unaffected carriers with germline VHL
mutations from 134 kindreds were analysed for the ‘‘VHL
modifier analysis’’ study. We also analysed a cohort of 317 Polish
sporadic RCC patients and 295 Polish normal controls that were
matched to the patients by sex and approximate year of birth and
were ascertained from the same region. The Polish sporadic RCC
patients consisted of 226 men (mean age at diagnosis of RCC 60.7
years (range 26–89 years)) and 117 women (mean age at diagnosis
of RCC 60.2 years (range 17–84 years)). The Polish normal
controls consisted of 204 men (mean age 64 years (range 40–90
years)) and 117 (mean age 63.6 years (range 24–91 years)). All
controls had a negative cancer family history. The study protocol
was approved by the local Research Ethics bodies and participants
gave informed consent.
Molecular Genetic Studies
VHL mutation analysis in the VHL patient cohort was
performed by direct sequencing and MLPA analysis and the
mutation analysis results have been reported previously [20].
Genotyping of candidate functional polymorphisms in CDH1
(rs16260 promoter variant c.-C160A), IGFBP3 (rs2854744 pro-
moter variant c.-C202A), MMP1 (rs1799750 promoter variant c.-
1607 2G/1G), MMP3 (rs679620 c.A198G R Lys45Glu), STK15
(rs2273535 c.T91A R Phe31Ile) and VEGF (rs1570360 promoter
variant c.-G1154). were performed by competitive allele specific
PCR system (KASPar, KBiosciences). Details of primers and
reaction conditions are available on request.
Statistical analysis
For the ‘‘VHL modifier analysis’’ study Kaplan-Meir survival
curves were constructed and Cox regression analysis was
performed to determine with the effect of different CDH1,
IGFBP3, MMP1, MMP3, STK15 and VEGF alleles on age at onset
of renal, retinal and cerebellar tumours in VHL patients.
For analysis of sporadic RCC patients and controls, deviation
from Hardy Weinberg proportions for the genotypes of both
markers and linkage disequilibrium between marker alleles was
tested by x2 tests. We calculated odds ratios (OR) and
corresponding 95% confidence intervals (95%CI) using logistic
regression for genotypic, allelic and haplotypic analyses. We
estimated the false-positive report probability (FRFP) for statisti-
cally significant observations using the methodology described by
Wacholder et al [21]. This method assumes that the prior
probability that the association between a genetic variant and a
disease is real is likely to be influenced by knowledge of the
biological function of a gene and previous evidence that an
association exists. The FRFP is calculated for a range of prior
probabilities (50% to 0.1%). A prior probability of 50% might be
appropriate when there is strong biological plausibility and
consistent previous evidence for an association, whilst a prior
probability of 0.1% would be appropriate when there is no
biological or previous supporting evidence for an association. We
selected the prior probabilities for the calculation of FRFP for our
data according to the pre-existing evidence for likely association
with RCC. Thus the MMP1 promoter polymorphism (rs1799750)
has been shown previously to influence expression of the MMP1
gene [22] and has been reported previously to be associated with
risk of RCC and other cancers in [23–26]. In the light of this prior
probabilities of 25% (and 10%) were assigned [21]. The STK15
rs2273535 missense substitution has been reported previously to
alter the STK15 function [27] and to be associated with numerous
number of different cancer types [28–31]. However, in a previous
study, no statistically significant association between rs2273535
and RCC risk was detected [13]. Hence more conservative prior
probabilities (1%–10%) were selected for the calculation of FRFP.
In accordance with Wacholder et al [21] a standard FRFP cut-off
of less than 0.5 was selected with a cut-off of 0.2 being considered
more stringent.
A Bayesian statistical method for reconstructing uncertain
haplotypes was applied by using the program PHASE [32] version
2.1. For allelic and haplotypic analyses, the Huber sandwich
estimator of variance [33] have been calculated to take into
account the clustering of two chromosomes within individuals.
The most frequent haplotype (1G/G) was used as the reference
haplotype. An omnibus likelihood ratio based test was performed
to investigate whether the regression coefficient of at least one of
the haplotypes in the model is not equal to zero. In the results the
omnibus test showed no significance (p=0.09). All statistical
analyses were performed using Stata 9.0 [34].
Results
VHL Modifier Analysis and variants in CDH1, IGFBP3,
MMP1, MMP3, STK15 and VEGF
Analysis of genotypes of candidate functional modifiers in 6
genes was performed using a Cox proportional hazard model
analysis such that all the variables were entered into the regression
model and then non-significant (P.0.1) variables removed. For
RCC risk, the final model (overall x2=11.9336 P=0.0026)
retained only MMP1 and MMP3 (P=0.0291 and 0.0006731) and
excluded SNPs in CDH1, IGFBP3, STK15 and VEGF as significant
variables. VHL patients homozygous for the p.45Glu MMP3 allele
(rs679620 c.198G) had an earlier onset of RCC than those
homozygous for the p.45Lys MMP3 allele (rs679620 c.198A) and
heterozygotes had an intermediate risk (see Figure 1A). Similarly,
homozygotes for the ‘‘high-risk’’ MMP1 allele (rs1799750, c.-1607
2G) had an earlier onset of RCC than patients homozygous for the
‘‘low risk’’ MMP1 allele (rs1799750, c.-1607 1G), with heterozy-
gotes having an intermediate risk (see Figure 2A).
To determine if the observed modifier effects of MMP1 and
MMP3 variants extended to other features of VHL disease, we
repeated the Cox proportional hazard model analysis for age at
diagnosis of retinal and cerebellar haemangioblastomas. This gave
similar results, albeit less significant, to those for RCC. Thus for
retinal angiomas the final model (overall x2=7.04 P=0.0296)
retained MMP1 (rs1799750) and MMP3 (rs679620) (P=0.012 and
P=0.041 respectively) and likewise, for cerebellar haemangioblas-
toma (overall model fit x2=5.99 P=0.0499) only MMP1
(rs1799750) and MMP3 (rs679620) were retained (P=0.028 and
P=0.055 respectively) and CDH1 (rs16260), IGFBP3 (rs2854744),
STK15 (rs2273535) and VEGF (rs1570360) were excluded. As for
RCC, homozygotes for the ‘‘high-risk’’ MMP1 allele (rs1799750,
c.-1607 2G) had an earlier age at diagnosis of retinal angioma and
cerebellar haemangioblastoma than patients homozygous for the
‘‘low risk’’ MMP1 allele (rs1799750, c.-1607 1G) (Fig 2B and 2C)
and homozygotes for the p.45Glu MMP3 allele (rs679620 c.198G)
had earlier age at diagnosis of retinal angioma and cerebellar
haemangioblastoma than those homozygous for the p.45Lys
MMP3 allele (rs679620 c.198A (see Fig 1B and Fig 1C).
RCC Association Study for variants in CDH1, IGFBP3,
MMP1, MMP3, STK15 and VEGF
317 RCC patients and 295 controls were analysed for six
polymorphic variants in six candidate RCC susceptibility genes.
All genotypes were in Hardy Weinberg equilibrium. Comparison
Genetics of Renal Cancer
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between patients and controls for MMP1 rs1799750 and STK15
rs2273535 polymorphic variants (see Table 1).
For the MMP1 rs1799750 polymorphic variant, the ‘‘high-risk’’
MMP1 allele (c.-1607 2G, that was associated with an earlier onset
of RCC in VHL patients) was significantly increased in the Polish
sporadic RCC patients compared to controls (p=0.049 OR 1.25,
95%CI 1.003–1.55)(See Table 1). Additionally the homozygous
genotype containing the ‘‘high-risk’’ MMP1 allele (rs1799750, c.-
1607 2G) was significantly increased in the Polish sporadic RCC
patients compared to controls (p=0.030 OR 1.47, 95%CI 1.04–
2.07)(See Table 1). According to the criteria of Wacholder et al
[21], this result remained robust given the appropriate prior
probabilities of 25% (FRFP=0.139) and 10% (FRFP=0.362).
Although there were no significant differences between RCC
patients and controls for MMP3 rs679620, there was strong
evidence of linkage disequilibrium between MMP1 rs1799750 and
MMP3 rs679620 (D’=0.50, x
2=92.4, P,0.001). In the light of
Figure 1. Effect of MMP3 rs679620 genotype on tumour risk in VHL disease. Panel A: VHL patients homozygous for the p.45Glu MMP3
allele (rs679620 c.198G) had an earlier onset of RCC than those homozygous for the p.45Lys MMP3 allele (rs679620 c.198A) and heterozygotes had an
intermediate risk. Similar associations were also found for onset of cerebellar haemangioblastoma and retinal angioma (see panels B and C
respectively).
doi:10.1371/journal.pone.0006037.g001
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risks to the reference haplotype rs1799750, c.-1607 1G/rs679620,
198G demonstrated a significant increased risk for rs1799750, c.-
1607 2G/rs679620, 198G (OR 1.45, 95%CI 1.01–2.10) but not
for rs1799750, c.-1607 1G/rs679620, 198A (OR 0.9, 95%CI
0.62–1.31) or rs1799750, c.-1607 2G/rs679620, 198A (OR 1.21,
95%CI 0.95–1.55) haplotypes. Thus the combination of the two
alleles associated with increased tumour risk in VHL patients was
also associated with the highest risk.
For the STK15 rs2273535 polymorphic variant, the homozy-
gous genotype containing the p.31Ile STK15 allele (c.91A) was
significantly increased in the Polish sporadic RCC patients
Figure 2. Effect of MMP1 rs1799750 genotype on tumour risk in VHL disease. Panel A: Homozygotes for the ‘‘high-risk’’ MMP1 allele
(rs1799750, c.-1607 2G) had an earlier onset of RCC than patients homozygous for the ‘‘low risk’’ MMP1 allele (rs1799750, c.-1607 1G), with
heterozygotes having an intermediate risk. Similar associations were also found for onset of cerebellar haemangioblastoma and retinal angioma (see
panels B and C respectively).
doi:10.1371/journal.pone.0006037.g002
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Table 1). The addition of the Polish familial RCC patients
increased the significance (p=0.027 OR 1.42, 95%CI 1.04–1.94).
This result remained robust at a prior probability of 10%
(FRFP=0.365) but not with a prior probability of 1%
(FRFP=0.865).
Discussion
Our findings suggest that functional SNPs in MMP1/MMP3
can influence susceptibility to RCC in familial (VHL disease) and
sporadic patients and that MMP1 rs1799750 and MMP3 rs679620
genotypes can also influence the risk of retinal angioma and
cerebellar haemangioblastoma in VHL disease. The ability to
invade normal tissue and metastasise is a key feature of malignant
neoplasms and the matrix metalloproteinase family of zinc-
dependent enzymes (MMPs) have a key role in degrading the
extracellular matrix and facilitating tissue invasion by cancer cells.
In addition, MMPs may regulate availability of growth factors and
enhance angiogenesis [35–37]. Matrix metalloproteinase 1
(MMP1) has a specific ability to degrade type-I collagen (the most
abundant substrate in the tumour surrounding stroma) and has
been implicated in tumour invasion and metastasis [38], whereas
MMP3 degrades a broader range of substrates (e.g. fibronectin,
laminin, collagens III, IV, IX, and X, and cartilage proteoglycans),
and may also affect the expression of other MMPs [39]. The
Table 1. Genotyping data for sporadic RCC cases.
Gene SNP Controls Sporadic RCCs
Fisher’s
P-value OR (95%CI)
CDH1 rs16260 C A C A 0.537 1.08 (0.85–1.38)
444 (72%) 174 (18%) 458 (70%) 194 (30%)
CC/CA AA CC/CA AA 0.777 1.11 (0.63–1.94)
284 (92%) 25 (8%) 297 (91%) 29 (9%)
CC CA/AA CC CA/AA 0.579 1.10 (0.81–1.50)
160 (52%) 149 (48%) 161 (49%) 165 (51%)
IGFBP3 rs284744 C A C A 0.288 1.13 (0.90–1.43)
376 (64%) 214 (36%) 381 (61%) 246 (39%)
CC/CA AA CC/CA AA 0.125 1.45 (0.90–2.33)
262 (89%) 33 (11%) 268 (85%) 49 (15%)
CC CA/AA CC CA/AA 0.452 1.14 (0.82–1.58)
114 (39%) 181 (61%) 113 (36%) 204 (64%)
MMP1 rs1799750 1G 2G 1G 2G 0.049 1.25 (1.00–1.56)
306 (49%) 322 (51%) 279 (43%) 367 (57%)
2G1G/1G1G 2G2G 2G1G/1G1G 2G2G 0.030 1.47 (1.04–2.07)
234 (75%) 80 (25%) 215 (67%) 108 (33%)
1G1G 2G2G/2G1G 1G1G 2G2G/2G1G 0.194 1.20 (0.82–1.76)
72 (23%) 242 (77%) 64 (20%) 259 (80%)
MMP3 rs679620 G A G A 0.866 1.03 (0.82–1.28)
330 (53%) 288 (47%) 342 (53%) 306 (47%)
GG/GA AA GG/GA AA 0.286 1.09 (0.63–1.94)
243 (78%) 66 (22%) 250 (77%) 74 (23%)
GG GA/AA GG GA/AA 0.509 0.99 (0.70–1.40)
87 (28%) 222 (72%) 92 (28%) 232 (72%)
STK15 rs2273535 A T A T 0.063 0.78 (0.60–101)
464 (74.5%) 158 (25.5%) 519 (80%) 137 (20%)
AA/AT TT AA/AT TT 0.725 0.82 (0.24–2.79)
293 (94%) 18 (6%) 312 (95%) 16 (5%)
AA AT/TT AA AT/TT 0.044 0.71 (0.52–0.98)
171 (55%) 140 (45%) 207 (63%) 121 (37%)
VEGF rs1570360 G A G A 0.159 1.18 (0.94–1.49)
422 (67%) 206 (33%) 411 (63%) 237 (37%)
GG/GA AA GG/GA AA 0.415 1.23 (0.78–1.95)
276 (92%) 38 (92%) 277 (92%) 47 (92%)
GG GA/AA GG GA/AA 0.202 1.23 (0.90–1.68)
146 (92%) 168 (92%) 134 (92%) 190 (92%)
doi:10.1371/journal.pone.0006037.t001
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shown to influence MMP1 transcription in both normal fibroblasts
and in melanoma cells [22]. An inverse correlation between
MMP1 expression and cancer prognosis has been reported in
many cancers [40–42] and the rs1799750 variant has been linked
with an increased risk of developing lung, ovarian, colorectal, and
head and neck cancers [24–26]. In addition, Hirata et al (2003)
reported an increased frequency of the rs1799750 2G variant in
RCC cases (n=119) from Japan compared to population controls
(n=210) [23]. We have replicated this finding in a larger cohort of
RCC patients from a different ethnic group.
The rs679620 A MMP3 p.K45E polymorphism in the matrix
metalloproteinase 3 (stromelysin-I) gene has been associated
previously with differences in MMP3 activity and has been linked
to cancer susceptibility in some studies [43–45]. Association studies
of MMP1 and MMP3 SNPs are complicated by the colocation of
these two genes within a MMP gene cluster at 11q22.3 and we
detected evidence of strong linkage disequilibrium between
rs1799750 and rs679620. A previous study demonstrated an
association between a rs1799750 and rs679620 haplotype
consisting of the MMP1 1G/2G polymorphism and the MMP3
Glu45Lys polymorphism. Hence we investigated both variants
separately and as a combined haplotype. This demonstrated that
the strongest link with RCC was associated with the MMP1
rs1799750 2G/MMP3 rs679620 G haplotype. Again this is
consistent with the findings of Hirata et al (2004) who reported
that the frequency of the same allelic haplotype was significantly
higher in the RCC patients of Japanese descent than in the
controls (crude OR=1.95, 95%CI=1.31–2.91).
We did not find any evidence that the tested genetic variants in
CDH1 (rs16260), IGFBP3 (rs2854744), VEGF (rs1570360) and
STK15 (rs2273535) influenced risk of RCC in VHL disease
patients. Unlike MMP1 and MMP3, none of these variants has
previously been associated with RCC risk in sporadic patients
[13]. Thus there would appear to be a good correlation between
variants that can modify RCC risk in VHL and those that have
been reported to be associated with RCC risk in sporadic RCC
patients. However, there are two caveats to this observation.
Firstly it is possible that that these variants might be demonstrated
an effect in larger studies. Secondly, we detected a statistically
significant association between a genetic variant (rs2273535) in
STK15 and RCC in sporadic patients. STK15 (Aurora-A) is a
serine/threonine kinase essential for chromosome segregation and
cytokinesis. Overexpression of STK15 is common in many cancers
and is associated with centrosome amplification, chromosome
instability and cell transformation [46]. Previously the STK15
(rs2273535, p.Phe31Ile) variant was found to alter the potency of
STK15 transformation [27] and was reported to be associated
with cancer risk in a number of cancer types including ovarian,
colorectal, breast, oesophagus and lung [28–31]. Although,
Hammerschmeid et al [13] did not detect a significant association
between the p.Phe31Ile variant and RCC, the patient and control
study groups (n=156 and n=158 respectively) were less than half
as many as those analysed by us and so further analysis of a larger
groups is indicated.
We estimated the false-positive reporting probability (FPRP) for
our results by incorporating a range of prior probabilities that
specific polymorphisms are associated with RCC risk [21,47]. The
association between the MMP1 genotype and RCC risk was
extremely robust with a prior probability of 25% (FRFP=0.139)
(and remained robust if the prior probability was reduced to 10%).
Given that the pre-existing evidence for an association between the
STK15 p.Phe31Ile variant and RCC was less secure a lower prior
probability (10%) was selected. Whilst the FRFP was still in favour
of a real association (FRFP=0.365) at this prior probability, it
should be emphasised that the putative STK15 association should
be confirmed in larger cohorts.
Previously, we reported that the phenotypic expression of VHL
disease is influenced by modifier effects and that patients with
more severe retinal angiomatosis also had increased age-related
risks of cerebellar haemangioblastomas and RCC [10]. Subse-
quently, we reported that a functional variant in the VHL target
gene CCND1 influenced risk of retinal angiomas and central
nervous system hemangioblastomas (but not RCC) in VHL disease
patients [11]. Hence the finding of an association between MMP1
and MMP3 genotypes and RCC risk represents the first examples
of genetic modifiers of RCC risk in VHL disease. In addition, the
observation that MMP1 and MMP3 genotypes also appeared to
influence retinal angioma and cerebellar haemangioblastoma risks
is consistent with our previous report suggesting shared genetic
modifiers of retinal angiomatosis, cerebellar haemangioblastomas
and RCC risks in VHL disease [10]. Previously, pVHL was
reported to downregulate metalloproteinases, such as MMP1, and
upregulate MMP inhibitors (TIMPs) [48], so it is not unreasonable
to suggset that genetic variants in MMP/TIMP pathways might
influence tumourigenesis in VHL disease. In addition, as somatic
VHL inactivation occurs in most clear cell RCC, and this
histopathology accounts for ,75% of all sporadic RCC, it is not
unexpected that genetic modifiers of VHL disease RCC risk,
might also function as low penetrance RCC susceptibility alleles
(e.g. the association between MMP1/MMP3 hapolotypes and
RCC). Both STK15 and pVHL have been linked to p53 function
[49–50], but although we found evidence for an association
between STK15 rs2273535 31Ile genotype and RCC susceptibility,
there was no apparent evidence of modifier effects in VHL disease.
Further studies are required to confirm the role of STK15 variation
in RCC susceptibility but it could be that the influence of germline
STK15 variants is predominantly on a VHL-independent
pathway of renal tumourigenesis. Our findings suggest that
functional genetic variants in VHL-related pathways should be
further evaluated as candidate genetic modifiers in VHL disease
and as RCC susceptibility alleles. The identification of common
variants associated with RCC risk in VHL and sporadic patients
could provide further insights into RCC biology and highlight
candidate familial RCC genes suitable for resequencing studies to
detect rare high penetrance mutations.
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